UPDATE 1-Human Genome seeks FDA nod to market lupus drug

* Says files Biologics License Application with FDA

* Lupus drug being co-developed with Glaxo

June 10 (Reuters) - Human Genome Sciences Inc (HGSI.O) said it has sought for U.S. regulatory approval to market its experimental lupus drug Benlysta that the biopharmaceutical company is co-developing with partner GlaxoSmithKline Plc (GSK.L).

The Biologics License Application submission to the Food and Drug Administration includes results from two later stage trials, the company said.

The drug, also known as belimumab, is being developed for the treatment for lupus -- a complex disease that causes the immune system to attack the body's own tissue and organs.

If approved, it will be the first new drug for systemic lupus in more than 50 years, the company said.

Earlier in the week, partner Glaxo had filed for a marketing application of the drug with the European Medicines Agency. [ID: nSGE6560EX]

Shares of Human Genome were up 2 percent at $24.29 in pre-market trade Thursday. They closed Wednesday at $23.82 on Nasdaq. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Vyas MOhan)